Packaging, Safety, Therapy and Treatment

How to access and assess ketamine therapy options

The Cannigma

MAY 15, 2023

Ketamine has a long safety record as an anesthetic since the 1980s, and it has also been successfully used “off-label” for over a decade to treat conditions such as anxiety, depression, OCD, and PTSD, among others. Patients may want to seek assistance from a certified professional prior to embarking on treatment.

Therapy

Therapy Access Blood Pressure Treatment

A NORML Reminder: Beware of COVID-19 Cure All Claims

NORML

MARCH 23, 2020

For example, one recent CBD provider recently received warning letters from the US Food and Drug Administration and the Federal Trade Commission for improperly marketing the agent as a key component of its COVID-19 prevention package. A greater discussion of these cannabis safety guidelines are available from NORML here.).

CBD

CBD Therapy Treatment Packaging

Maryland’s Medical Cannabis Market: Updates on Dispensary Services and Card Renewals

MMJ Recs

MARCH 20, 2024

Many dispensaries also offer additional services such as educational resources, patient consultations, and ongoing support programs to address patient concerns and enhance their overall treatment experience.

Dispensary

Dispensary Programs Access Patients

Press Release: Numinus Wellness research facility licensed by Health Canada to supply psilocybin mushrooms

Cannabis Law Report

JANUARY 31, 2022

Numinus Bioscience said that it is prepared to supply psilocybin in whole mushroom form, through three packaged doses equivalent to 10, 15, and 25mg of psilocybin. At this time, Numinus Bioscience said that it is prepared to supply psilocybin in whole mushroom form, through three packaged doses equivalent to 10, 15, and 25mg of psilocybin.

Research and Development

Research and Development Clinical Trials Packaging Access

ElleVet Sciences Publishes Safety Study On CBD For Animals

Cannabis Law Report

OCTOBER 29, 2019

ElleVet Sciences is pleased to announce the results and publication of the first safety study on the use of hemp CBD/CBDA. The 12-week safety study, conducted by Dr. Joseph Wakshlag, DVM, Ph.D., Dr. Wakshlag is currently available for interviews to discuss the results of the safety study as well as his clinical trials.

Safety

Safety CBD Clinical Trials Oil

Navigating Ohio’s Medical Marijuana Dispensaries: A Comprehensive Guide for Patients

MMJ Recs

MARCH 2, 2024

Observing discretion in discussions regarding medical conditions and treatment enhances privacy and respect among patrons. Additionally, adhering to dispensary policies on product handling and consumption promotes harmony and safety.

Dispensary

Dispensary Patients Marijuana Education

Marijuana Edibles: Everything You Need to Know

CannaMD

MAY 14, 2020

CannaMD has contacted Florida’s leading medical marijuana treatment centers (MMTCs) , who say they’re now just waiting on the Department of Health to issue rules regarding packaging and other essential requirements. Safety of production and packaging. Risks of over-consumption and accidental ingestion.

Edibles

Edibles Marijuana THC Vaping

Q&A with Mason Marks on New Psychedelics Law and Regulation Initiative @ Harvard

Cannabis Law Report

JULY 1, 2021

In 2017, the FDA designated MDMA a breakthrough therapy for post-traumatic stress disorder, and in 2018 the agency recognized psilocybin as a breakthrough therapy for treatment-resistant depression. Mason Marks: The project’s goal is to promote safety, innovation, equity, and accessibility in emerging psychedelics industries.

Law

Law Research and Development Therapy DEA

The FDA Continues to Chase CBD Companies

Canna Law Blog

APRIL 27, 2020

According to the FDA’s press release : The opioid crisis continues to be a serious problem in the United States, and we will continue to crack down on companies that attempt to benefit from selling products with unfounded treatment claims,” said FDA Principal Deputy Commissioner Amy Abernethy, M.D.,

CBD

CBD Topical Oil Treatment

Every California Dispensary That MMJ Patients Need To Know

MMJ Recs

OCTOBER 2, 2023

California has been a trailblazer in the realm of medical marijuana, offering patients access to a variety of treatment options. If the doctor determines that medical cannabis is a suitable treatment option, they will provide a recommendation for the patient. You can find CA medical marijuana doctors online on sites like MMJRecs.

Dispensary

Dispensary Patients Environment Conditions

FDA Publish Article “5 Things to Know about Delta-8 Tetrahydrocannabinol – Delta-8 THC”

Cannabis Law Report

SEPTEMBER 15, 2021

This deceptive marketing of unproven treatments raises significant public health concerns because patients and other consumers may use them instead of approved therapies to treat serious and even fatal diseases. Thus, historical use of cannabis cannot be relied upon in establishing a level of safety for these products in humans.

THC

THC Pets Events Hemp

InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial

Puff Puff Post

NOVEMBER 5, 2019

INM-755 is a single-cannabinoid topical cream under development for the treatment of symptoms associated with epidermolysis bullosa (“EB”). Two strengths of INM-755 cream will be evaluated in 22 adult subjects over a 14-day treatment period. Most types of epidermolysis bullosa are inherited. About INM-755.

Clinical Trials

Clinical Trials Pharmaceutical Cannabinoids Data

Lighting Up Florida’s Medical Marijuana People: The Medics Series, Part 5

Cannabis Law Report

JULY 30, 2019

In the 2018 issue of the INvisibleProject.org ‘s annual “ Medical Cannabis: One Therapy, Many Journeys ,” Ellen Lenox Smith believes it is imperative for society to understand the following fact about medical cannabis: “ it is an indigenous plant found in nature that is non-invasive and safe. Pain Foundation.

Marijuana

Marijuana Education Patients Research and Development

InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial

Puff Puff Post

NOVEMBER 5, 2019

INM-755 is a single-cannabinoid topical cream under development for the treatment of symptoms associated with epidermolysis bullosa (“EB”). Two strengths of INM-755 cream will be evaluated in 22 adult subjects over a 14-day treatment period. Most types of epidermolysis bullosa are inherited. About INM-755.

Clinical Trials

Clinical Trials Pharmaceutical Cannabinoids Data

Medical Cannabis Brief

How to access and assess ketamine therapy options

A NORML Reminder: Beware of COVID-19 Cure All Claims

Trending Sources

Maryland’s Medical Cannabis Market: Updates on Dispensary Services and Card Renewals

Press Release: Numinus Wellness research facility licensed by Health Canada to supply psilocybin mushrooms

ElleVet Sciences Publishes Safety Study On CBD For Animals

Navigating Ohio’s Medical Marijuana Dispensaries: A Comprehensive Guide for Patients

Marijuana Edibles: Everything You Need to Know

Q&A with Mason Marks on New Psychedelics Law and Regulation Initiative @ Harvard

The FDA Continues to Chase CBD Companies

Every California Dispensary That MMJ Patients Need To Know

FDA Publish Article “5 Things to Know about Delta-8 Tetrahydrocannabinol – Delta-8 THC”

InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial

Lighting Up Florida’s Medical Marijuana People: The Medics Series, Part 5

InMed Submits Clinical Trial Application to Evaluate INM-755 in Phase 1 Trial

Stay Connected